Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 3
1990 1
1992 2
1993 1
1994 1
1998 1
2000 1
2006 1
2008 1
2009 6
2010 6
2011 7
2012 6
2013 4
2014 6
2015 2
2016 1
2018 2
2019 3
2020 4
2021 3
2022 2
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: hashimura y. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Iijima K, et al. Lancet. 2014 Oct 4;384(9950):1273-81. doi: 10.1016/S0140-6736(14)60541-9. Epub 2014 Jun 22. Lancet. 2014. PMID: 24965823 Clinical Trial.
Characterization of the Aeration and Hydrodynamics in Vertical-Wheel™ Bioreactors.
Neto PM, Nogueira DES, Hashimura Y, Jung S, Pedras B, Berberan-Santos MN, Palmeira T, Lee B, Cabral JMS, Geraldes V, Rodrigues CAV. Neto PM, et al. Among authors: hashimura y. Bioengineering (Basel). 2022 Aug 12;9(8):386. doi: 10.3390/bioengineering9080386. Bioengineering (Basel). 2022. PMID: 36004911 Free PMC article.
Segmental membranous nephropathy with severe IgG3 deposition.
Kondo A, Hashimura Y, Uchiyama T, Yoshikawa N, Minami H. Kondo A, et al. Among authors: hashimura y. Pediatr Int. 2018 Jun;60(6):597-598. doi: 10.1111/ped.13560. Epub 2018 May 9. Pediatr Int. 2018. PMID: 29744961 No abstract available.
X-linked Alport syndrome caused by splicing mutations in COL4A5.
Nozu K, Vorechovsky I, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, Hashimoto F, Kamei K, Ito S, Kaku Y, Imasawa T, Ushijima K, Shimizu J, Makita Y, Konomoto T, Yoshikawa N, Iijima K. Nozu K, et al. Among authors: hashimura y. Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1958-64. doi: 10.2215/CJN.04140414. Epub 2014 Sep 2. Clin J Am Soc Nephrol. 2014. PMID: 25183659 Free PMC article.
Natural history of genetically proven autosomal recessive Alport syndrome.
Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, Morisada N, Yan K, Matsuo M, Yoshikawa N, Vorechovsky I, Iijima K. Oka M, et al. Among authors: hashimura y. Pediatr Nephrol. 2014 Sep;29(9):1535-44. doi: 10.1007/s00467-014-2797-4. Epub 2014 Mar 15. Pediatr Nephrol. 2014. PMID: 24633401
57 results